Glenmark Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 12 analysts polled by S&P Global, Glenmark Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of ₹2,497. The average 1-year stock price forecast is 9.31% higher than the current stock price, while the lowest is ₹2,100 (-8.08%) and the highest is ₹2,750 (+20.38%).

Price Target: ₹2,497 (+9.31%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	₹2,100	₹2,497	₹2,575	₹2,750
Change	-8.08%	+9.31%	+12.72%	+20.38%

* Price targets were last updated on Feb 3, 2026.

Analyst Ratings

The average analyst rating for Glenmark Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	Jun '26	Jul '26
Strong Buy	8	7	7	7	6	6
Buy	2	3	3	2	3	4
Hold	1	1	1	1	2	2
Sell	0	0	0	0	0	0
Strong Sell	1	1	1	1	0	0
Total	12	12	12	11	11	12

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Abdulkader Puranwala ICICI Securities	ICICI Securities	Sell Maintains ₹1,640	Sell	Maintains	₹1,640	-28.21%	Feb 3, 2026
Unknown Analyst Motilal Oswal No rating	Motilal Oswal	Buy Maintains ₹2,240	Buy	Maintains	₹2,240	-1.95%	Feb 2, 2026

Financial Forecast

Revenue This Year

166.72B

from 169.83B

-1.83%

from 169.83B

Revenue Next Year

185.36B

from 166.72B

11.18%

from 166.72B

EPS This Year

81.04

from 103.32

-21.57%

from 103.32

EPS Next Year

98.29

from 81.04

21.29%

from 81.04

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024	Mar 31, 2025	Mar 31, 2026	Mar 31, 2027
Revenue	123.05B	116.56B	126.45B	133.63B	169.83B	166.72B
Revenue Growth	12.44%	-5.28%	8.49%	5.68%	27.08%	-1.83%
Gross Profit	77.57B	72.45B	80.66B	88.38B	122.35B	114.66B
Gross Margin	63.04%	62.16%	63.79%	66.14%	72.04%	68.78%
Operating Income	18.40B	11.38B	14.46B	19.07B	39.99B	30.34B
Net Income	9.42B	2.97B	-15.02B	10.47B	13.62B	23.28B
EPS	-	-	-	-	103.32	81.04
EPS Growth	-	-	-	-	119.84%	-21.57%
Forward PE	10.59	10.10	26.45	26.02	26.04	28.19
Dividend / Share	2.50	2.50	2.50	2.50	5.00	5.36
Dividend Growth	-	-	-	-	100.00%	7.18%
Free Cash Flow	1.85B	-11.60B	43.25B	-16.06B	11.77B	16.41B
No. Analysts	-	-	-	-	-	9

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.

Revenue Forecast

Revenue	2027	2028	2029
High	185.4B
Avg	166.7B
Low	150.4B

Revenue Growth

Revenue Growth	2027	2028	2029
High	9.2%
Avg	-1.8%
Low	-11.4%

EPS Forecast

EPS	2027	2028	2029
High	89.95
Avg	81.04
Low	60.40

EPS Growth

EPS Growth	2027	2028	2029
High	-12.9%
Avg	-21.6%
Low	-41.5%